RxDoctor Payments Data

Vedampattu Ganeshram, MD

Cardiovascular Disease · Wichita Falls, TXNPI 1407818669

Payments from drug & device makers

$58,352in general payments, 2019–2025

Across 371 payments — averaging $157.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • American Regent$24K
  • Pfizer$9K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Abbott$7K
  • Amgen$5K
  • Novartis$1K
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$5002%
  • Speaking & faculty fees$13,72362%
  • Travel & lodging$1,0285%
  • Food & beverage$6,85431%
  • Education$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,352 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$560,285
Medicare patients
2,120
Services billed
9,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,615$1,668,737
XareltoRivaroxaban284$269,239
EntrestoSacubitril/Valsartan111$134,253
Repatha SureclickEvolocumab45$34,644
Metoprolol Succinate1,729$30,511
BrilintaTicagrelor29$30,319
Dabigatran EtexilateDabigatran Etexilate Mesylate91$19,762
Repatha SyringeEvolocumab23$17,642
JardianceEmpagliflozin17$17,236
Ranolazine ErRanolazine114$14,011
VascepaIcosapent Ethyl15$11,427
Digoxin201$10,847
Diltiazem 24hr Er (Cd)Diltiazem Hcl340$10,510
Atorvastatin Calcium1,145$8,673
Valsartan318$8,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8,918$1,668,7371,615 claims
Johnson & JohnsonXarelto$354$269,239284 claims
NovartisEntresto$1,056$134,253111 claims
AstraZenecaBrilinta$452$30,31929 claims
Boehringer IngelheimJardiance, Pradaxa$375$22,36428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →